April 1, 2022 – The activation of the bone marrow appears to play a key role in the origin and development of atherosclerosis, the pathological process underlying cardiovascular conditions such as myocardial infarction and stroke. A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and led by cardiologists Valentín Fuster and Borja Ibáñez suggests that the bone marrow is activated in response to known cardiovascular risk factors. In the study, published in the European Heart Journal, the researchers show that these risk factors lead to an increase in the number of circulating inflammatory cells, which go on to trigger the initiation and subsequent progression of atherosclerotic disease.
Atherosclerosis is a progressive deposition of fats and inflammatory cells in the arterial wall, resulting in the formation of atheroma plaques. After many years of silent, symptom-free growth and development, atheroma plaques can erode or rupture, resulting in a superimposed thrombus that can trigger acute myocardial infarction, stroke, or sudden cardiac death.
Atherosclerosis is the most frequent cause of death in the world and is considered a ‘silent killer’ because it develops quietly for years before producing symptoms. Identifying atherosclerosis in its initial phases, before symptoms appear, is a major goal of the PESA-CNIC-Santander (Progression of Early Subclinical atherosclerosis) study. This study was launched in 2010 as a collaboration between the CNIC and Santander Bank and is led by Dr. Valentín Fuster, CNIC Director General and cardiologist and Medical Director at Mount Sinai Hospital in New York.
The new study establishes a basis for fighting this disease by attacking the roots of its development. According to Borja Ibañez, CNIC Clinical Research Director, cardiologist at Hospital Universitario Fundación Jiménez Díaz, and a group leader in the Spanish cardiovascular research network (CIBERCV), “early detection of atherosclerosis allows us to gain knowledge about the mechanisms that produce it, opening avenues toward identifying new treatments able to prevent the progression of this fatal disease.”
Dr. Ibáñez, who directed the study together with Valentín Fuster, explained that although atherosclerosis has been investigated for many decades, the mechanisms that initiate the disease remain unclear.
CNIC cardiologist and study first author Ana Devesa explained that the cardiovascular risk factors that activate the bone marrow are those linked to metabolic syndrome: central obesity (the accumulation of abdominal fat), a high blood triglycerides, low HDL cholesterol, elevated blood glucose, insulin resistance, and high blood pressure.
These factors trigger an increase in metabolic activity in the blood marrow that can be detected with the advanced image techniques available at the CNIC, such as hybrid positron emission tomography (PET)–magnetic resonance imaging (MRI). “The increased metabolic activity of the bone marrow unleashes an inflammatory process that activates atherosclerosis, from its earliest stages through to the appearance of established plaques,” said Dr. Devesa.
January 30, 2024 
